TABLE 3.
Immune changes in women living with HIV undergoing chemoradiation for cervical cancer
| Study and reference | No of patients, total (WLWH) | FIGO disease stage | % of WLWH receiving ART | Immune markers assessed | Central outcomes |
|---|---|---|---|---|---|
| Siraprapasiri et al (2011) 68 | 29 (29) | NA | 96% | WBC, CD4, CD4%, ALC%, HIV‐VL |
No change in CD4% from baseline to last week of RT ↓ WBC (6771 vs 3903 cells/μL), ALC% (31.7% vs 17.5%), CD4 (388 vs 158 cells/μL) from baseline to last week of RT Four patients (14%) had increased HIV‐VL after treatment (2 on ART, 2 not on ART) |
| Grover et al (2018) 67 | 143 (96) | I‐IV | 95.8% | WBC, ANC | No difference in WBC and ANC nadir during treatment between WLWH and HIV‐negative women |
| Vendrell et al (2018) 69 | 61 (6) | IB‐IV | 67% | ANC | Possibly increased risk of grade 3–4 neutropenia during treatment for WLWH vs HIV‐negative women (16.7% vs 3.6%, p = 0.27) |
| Simonds et al (2015) 66 | 213 (36) | IB1‐IIIB | 100% | WBC, ANC | ↑ in rates of grade 3–4 leukopenia (30.6% vs 10.2%, p = 0.003) for WLWH vs HIV‐negative women |
| Einstein et al (2019) 70 | 40 (40) | IB2‐IVA | 100% | ALC | All patients had decreases in lymphocyte counts that were largely self‐limiting and manageable |
Abbreviations: ALC, absolute lymphocyte count; ANC, absolute neutrophil count; ART, antiretroviral therapy; HIV‐VL, HIV viral load; RT, radiation therapy; WBC, white blood cell; WLWH, women living with HIV.